Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Osimertinib combined with savolitinib in the treatment of EGFR mutated osimertinib resistant NSCLC with low copy number MET amplification There are unmet medical needs in patients who resist to to osimertinib; savolitinib plus osimertinib shows high response rate and prolong progression-free survival in high copy number MET amplification patients. This study is to explore the efficacy and safety of the combination of savolitinib and osimertinib in osimertinb resistant patients with low copy number MET amplification.

Trial Details

NCT ID
NCT07322783
Phase
PHASE2
Sponsor
Qingdao Central Hospital
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • • Drug: Savolitinib • Drug: Osimertinib Mesylate Tablets
Locations (sample)
  • Qingdao, China|36.06488,120.38042

Key Eligibility Criteria

  • 1\. Histologically or cytologically confirmed incurable advanced or metastatic non-small cell lung cancer who resistant to resistant to osimertinib…
  • 2\. At least 1 measurable lesion (RECIST 1.1). 3. MET amplification copy number below 5 by FISH. 4. Male or female patients age ≥18 years. 5. Easte…
  • 10\. Willingness to use contraception by a method that is deemed effective by the investigator by both males and female patients of child bearing p…
  • 11\. Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any stu…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →